Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Sponsor: The Netherlands Cancer Institute
Summary
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.
Official title: Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2018-03-07
Completion Date
2026-10-31
Last Updated
2025-06-08
Healthy Volunteers
No
Interventions
Atezolizumab
atezolizumab 1200 mg 5 cycles
Capecitabine
capecitabine 850 mg /m2 4 cycles
Oxaliplatin
oxaliplatin 100 mg/m2 4 cycles
Docetaxel
docetaxel 50 mg/m2 4 cycles
Locations (2)
Marieke van de Belt
Amsterdam, Netherlands
Catharina ziekenhuis
Eindhoven, Netherlands